Dermapharm Holding SE stock analysis
Dermapharm Holding SE (0A5J) Share Price & Analysis
0A5J Stock Chart & Stats
- Day’s Range
- EUR 38.35 - EUR 39.00
- 52-Week Range
- EUR 33.25 - EUR 51.70
- Previous Close
- EUR 38.30
- Volume
- N/A
- Average Volume (3M)
- 3,568
- Market Cap
- EUR 1.91B
- Enterprise Value
- EUR 3.31B
- Total Cash (Recent Filing)
- EUR 195.56M
- Total Debt (Recent Filing)
- EUR 1.17B
- Price to Earnings (P/E)
- 13.9
- Beta
- 0.58
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.28%
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Renewed Growth
The return to revenue growth alongside higher net and EBIT margins indicates improving operating execution. If sustained, stronger profitability can support reinvestment, resilience against cost pressure, and earnings growth across Dermapharm’s branded and manufacturing businesses.
Materially De-risked Balance Sheet
The sharp reduction in leverage materially improves financial flexibility and lowers refinancing risk. Combined with strong returns on equity, the balance sheet gives Dermapharm greater capacity to fund operations, absorb volatility, and pursue growth without excessive debt dependence.
Positive Cash Generation
Substantial operating and free cash flow demonstrates that reported earnings are supported by cash generation. This provides resources for debt reduction, product development, manufacturing investment, and shareholder returns, strengthening the durability of the pharmaceutical platform.
Bears Say
Declining Free Cash Flow Momentum
Although cash generation remains positive, the decline in free cash flow and weaker conversion from earnings reduce financial flexibility. Persistent deterioration could limit investment capacity, slow deleveraging, and make reported profit growth less valuable to shareholders.
Margin Sustainability Remains Uncertain
The recent margin improvement is encouraging, but performance below prior peaks and uneven gross margins suggest that mix, pricing, or cost conditions may not be stable. This uncertainty could constrain earnings visibility and make future profit expansion less predictable.
Limited Top-line Growth
Revenue growth has resumed but remains subdued, indicating limited near-term expansion in the existing portfolio. Without stronger product adoption, market penetration, or CDMO growth, Dermapharm may rely more heavily on margin gains and cost control to increase earnings.
Dermapharm Holding SE News
0A5J FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
What is Dermapharm Holding SE’s market cap?
When is Dermapharm Holding SE’s upcoming earnings report date?
How were Dermapharm Holding SE’s earnings last quarter?
Is Dermapharm Holding SE overvalued?
Does Dermapharm Holding SE pay dividends?
What is Dermapharm Holding SE’s EPS estimate?
How many shares outstanding does Dermapharm Holding SE have?
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dermapharm Holding SE?
What is the TipRanks Smart Score and how is it calculated?
Dermapharm Holding SE Stock Smart Score
Company Description
Dermapharm Holding SE
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hans-Georg Feldmeier
- Employees
- 3,619
- Website
- www.dermapharm.de
- Address
- Lil-Dagover-Ring 7, Grünwald, BV, 82031, DE
Dermapharm Holding SE (0A5J) Earnings & Revenues
0A5J Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 7 | 0 | 5 |
